Complex generics, biosimilars & specialty to be growth drivers: Lupin
While sustaining and growing its presence in the generics segment, Lupin is planning to invest heavily in developing high barrier products in complex generics, the presentation said.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Pharmaceuticals